Saba Capital Management’s BioPlus Acquisition Corp. Class A Ordinary Shares BIOS Stock Holding History

Saba Capital Management’s Portfolio BIOS Stock Details BIOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-323,142	Closed	-$3.5M	–	597
2023 Q3	$3.5M	Hold	323,142	–	–	0.08%	169
2023 Q2	$3.44M	Sell	323,142 -718,703	-69%	-$7.56M	0.09%	185
2023 Q1	$10.9M	Sell	1,041,845 -750,000	-42%	-$7.77M	0.21%	156
2022 Q4	$18.4M	Hold	1,791,845	–	–	0.25%	101
2022 Q3	$18M	Hold	1,791,845	–	–	0.2%	128
2022 Q2	$17.9M	Buy	1,791,845 +251,833	+16%	+$2.5M	0.21%	114
2022 Q1	$15.2M	Buy	+1,540,012	New	+$15.2M	0.22%	114

Saba Capital Management's BIOS Position: Q4 2023 in Review

Saba Capital Management sold out of BioPlus Acquisition Corp. Class A Ordinary Shares (BIOS) in Q4 2023, closing a stake of 323,142 shares — an estimated $3.5M sold.

Saba Capital Management first reported a position in BIOS in Q1 2022 and held it in 7 quarters. The position peaked at $18.4M in Q4 2022. 0 funds tracked by Wall St. Rank hold BIOS as of Q4 2023.

Saba Capital Management reported no remaining BioPlus Acquisition Corp. Class A Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Saba Capital Management sold 323,142 BioPlus Acquisition Corp. Class A Ordinary Shares shares in Q4 2023, an estimated $3.5M.
Saba Capital Management first reported a position in BioPlus Acquisition Corp. Class A Ordinary Shares in Q1 2022 and held it in 7 quarters.
Saba Capital Management's BioPlus Acquisition Corp. Class A Ordinary Shares position peaked at $18.4M in Q4 2022.
0 funds tracked by Wall St. Rank held BioPlus Acquisition Corp. Class A Ordinary Shares as of Q4 2023.

Based on Saba Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.